Last $24.20 USD
Change Today -0.25 / -1.02%
Volume 288.1K
TRNX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

tornier nv (TRNX) Snapshot

Open
$24.50
Previous Close
$24.45
Day High
$24.50
Day Low
$24.15
52 Week High
09/15/14 - $25.00
52 Week Low
11/6/13 - $15.17
Market Cap
1.2B
Average Volume 10 Days
264.0K
EPS TTM
$-0.61
Shares Outstanding
48.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TORNIER NV (TRNX)

tornier nv (TRNX) Related Bloomberg News

View More Bloomberg News

tornier nv (TRNX) Related Businessweek News

No Related Businessweek News Found

tornier nv (TRNX) Details

Tornier N.V., a medical device company, designs, manufactures, markets, and sells orthopedic products. It offers a portfolio of approximately 95 products, including joint replacement, trauma, sports medicine, and biologic products to treat extremity joints. The company also provides joint replacement products for hip and knee. It principally serves surgeons who treat musculoskeletal injuries; and disorders of the shoulder, elbow, hand, wrist, ankle, and foot. The company distributes and sells its products through approximately 145 direct sales representatives and 40 independent sales agencies in the United States; and 13 direct sales offices and 25 distributors in approximately 45 countries worldwide. Tornier N.V. is headquartered in Amsterdam, the Netherlands.

1,076 Employees
Last Reported Date: 02/21/14

tornier nv (TRNX) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $444.3K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $354.4K
Senior Vice President of International Commer...
Total Annual Compensation: $366.3K
Senior Vice President of U.S. Commercial Oper...
Total Annual Compensation: $358.8K
Chief Legal Officer, Senior Vice President an...
Total Annual Compensation: $285.7K
Compensation as of Fiscal Year 2013.

tornier nv (TRNX) Key Developments

Tornier N.V. Reports Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended June 29, 2014; Provides Earnings Guidance for the Third Quarter and Full Year of 2014

Tornier N.V. reported unaudited consolidated financial results for the second quarter and six months ended June 29, 2014. For the quarter, the company reported revenue was $86.9 million compared to second quarter 2013 revenue of $78.1 million, an increase of 11.2% as reported and 9.5% in constant currency. Adjusted EBITDA was $6.1 million compared to $7.3 million in the same quarter of the prior year. Operating loss was $7.955 million against $8.376 million a year ago. Loss before income taxes was $9.487 million against $12.117 million a year ago. Consolidated net loss was $10.448 million against $12.537 million a year ago. Basic and diluted net loss per share was $0.21 against $0.28 a year ago. Net cash used in operating activities was $3.262 million against net cash provided by operating activities of $1.323 million a year ago. Purchases of property, plant and equipment was $3.116 million against $1.949 million a year ago. Non-GAAP adjusted net loss was $9.755 million against $6.104 million a year ago. Non-GAAP adjusted net loss per basic and diluted share was $0.20 against $0.14 a year ago. For the six months, the company reported revenue of $175.875 million against $160.820 million a year ago. Operating loss was $12.984 million against $12.989 million a year ago. Loss before income taxes was $15.624 million against $18.973 million a year ago. Consolidated net loss was $15.685 million against $19.435 million a year ago. Basic and diluted net loss per share was $0.32 against $0.45 a year ago. Net cash provided by operating activities was $0.105 million against $17.741 million a year ago. Purchases of property, plant and equipment were $4.880 million against $4.778 million a year ago. Non-GAAP adjusted EBITDA was $15.591 million against $16.464 million a year ago. Non-GAAP adjusted net loss was $12.381 million against $10.274 million a year ago. Non-GAAP adjusted net loss per basic and diluted share was $0.25 against $0.24 a year ago. The company projects third quarter 2014 constant currency revenue to be in the range of $69 to $73 million, representing constant currency growth of 3.4% to 9.4% over the same period last year. Based on recent currency exchange rates, third quarter 2014 reported revenue is projected to be in the range of $70 to $74 million, representing growth of 4.8% to 10.8% over the same period last year. The company projects third quarter 2014 adjusted EBITDA to be in the range of $2 to $4 million, or 2.9% to 5.4% of reported revenue. The company is increasing full year guidance and now projects 2014 constant currency revenue to be in the range of $328 to $336 million, representing an increase of 5.5% to 8.1% over last year. Based on recent currency exchange rates, 2014 reported revenue is projected to be in the range of $331 to $339 million, representing an increase of 6.4% to 9.0% over last year. The company projects 2014 adjusted EBITDA to be in the range of $27 to $31 million, or 8.2% to 9.1% of reported revenue. The company expects to continue to record special charges relating to sales transition activities and distributor acquisitions, as well as OrthoHelix restructuring activities. Special charges are expected to total $5.3 million to $6.2 million for the year 2014, of which $1.4 million to $1.9 million are anticipated in the third quarter. The company also expects to record approximately $500,000 to $700,000 of inventory step-up charges in cost of goods sold during 2014, of which approximately $100,000 to $200,000 is expected to occur in the third quarter. In addition to the guidance provided in the earnings release, amortization expenses are estimated to be approximately $17.1 million to $17.5 million in 2014 compared to $15.9 million in 2013. The company anticipates interest expense for fiscal 2014 to be in the range of $5.1 million to $5.6 million.

Tornier N.V. to Report Q2, 2014 Results on Aug 07, 2014

Tornier N.V. announced that they will report Q2, 2014 results After-Market on Aug 07, 2014

Tornier N.V., Q2 2014 Earnings Call, Aug 07, 2014

Tornier N.V., Q2 2014 Earnings Call, Aug 07, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TRNX:US $24.20 USD -0.25

TRNX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cyberonics Inc $52.84 USD -1.15
Exactech Inc $23.83 USD -0.36
ICU Medical Inc $61.71 USD -1.25
Thoratec Corp $26.14 USD -0.26
Wright Medical Group Inc $31.57 USD -0.72
View Industry Companies
 

Industry Analysis

TRNX

Industry Average

Valuation TRNX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.6x
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TORNIER NV, please visit www.tornier.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.